Mark S. Shapiro - 13 May 2026 Form 4 Insider Report for TKO Group Holdings, Inc. (TKO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 May 2026, 16:30:56 UTC
Prior SEC filing
22 Jan 2026
Next SEC filing
23 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Robert Hilton, Attorney-in-fact

Key filing fact

Mark S. Shapiro filed Form 4 for TKO Group Holdings, Inc. (TKO) on 13 May 2026.

Key facts

  • This page summarizes Mark S. Shapiro's Form 4 filing for TKO Group Holdings, Inc. (TKO).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 13 May 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 22 Jan 2026.
  • Current net transaction value: +$1,999,868.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001345978 Primary reporting owner

SHAPIRO MARK S

Relationship
President and Chief Operating Officer., Director
Address
C/O TKO GROUP HOLDINGS, INC., 200 FIFTH AVENUE, 7TH FLOOR, NEW YORK
Signature
/s/ Robert Hilton, Attorney-in-fact
Signature date
13 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TKO transaction

Class A Common Stock

Purchase

Transaction value
$887,468
Shares
+4,807
Change %
+4.1%
Price
$184.62
Shares after
123,207
Date
13 May 2026
Ownership
Direct
Footnotes
F1, F2
TKO transaction

Class A Common Stock

Purchase

Transaction value
$1,112,400
Shares
+6,000
Change %
+4.9%
Price
$185.40
Shares after
129,207
Date
13 May 2026
Ownership
Direct
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reporting person's purchase of Class A common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 10,807 shares at a weighted average price per share of $185.05, with the reporting person's sales of 32,022 shares of Class A common stock at a price per share of $204.08 on January 5, 2026 and of 14,363 shares of Class A common stock at a price per share of $201.98 on January 22, 2026, which prior sales were made under a Rule 10b5-1 sell-to-cover instruction letter to satisfy the tax withholding obligation upon the vesting of previously granted equity awards. The reporting person paid to the Issuer $205,632.35, representing the full amount of the profit realized in connection with the short-swing transaction.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $184.04 to $184.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $185.06 to $186.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC remarks

President and Chief Operating Officer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .